Israeli biotech firm signs $320 million deal to sell drug in US, Canada

Details werden geladen...

https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-903198

Teilen bei Facebook
Teilen bei Twitter
Teilen bei Pinterest
Per Mail empfehlen

Israeli biotech firm signs $320 million deal to sell drug in US, Canada | The Jerusalem Post

D-PLEX100 is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent abdominal surgical site infections.